Understand the source comparison
GHRP-6 Acetate vs Other Growth Hormone Secretagogues: Potency and Side Effect Profiles
GHRP-6 sits within a family of growth hormone releasing peptides that includes GHRP-2, Hexarelin, Ipamorelin, and the orally bioavailable compound MK 677. Each binds to GHS-R1a but with different receptor affinity, selectivity, and downstream signaling effects
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- GHRP-6 sits within a family of growth hormone releasing peptides that includes GHRP-2, Hexarelin, Ipamorelin, and the orally bioavailable compound MK 677. Each binds to GHS-R1a but with different receptor affinity, selectivity, and downstream signaling effects. The table below maps key differentiators.
- GHRP-6 Acetate
- 5–15× baseline at 1–2 mcg/kg
- Moderate (dose-dependent)
- Minimal
- ~30 min (plasma clearance)
- Best balance of potency and tolerability for multi-dose daily protocols; mild appetite increase limits use in caloric restriction studies
- GHRP-2
- 10–20× baseline at similar dose
- Low
- ~30 min
- Higher GH output than GHRP-6 with less hunger signaling; preferred when appetite stimulation is undesirable
- Hexarelin
- 15–25× baseline
- Moderate (cortisol +20–40%)
- Most potent GH release but significant cortisol co-secretion and receptor desensitization after 14–21 days; unsuitable for long-term studies
- Ipamorelin
- 3–8× baseline
- None
- ~2 hours
- Highly selective for GH with no appetite, cortisol, or prolactin effects; lower peak output but preferred in studies requiring clean endocrine profiles
- MK-677 (Ibutamoren)
- 2–4× baseline (continuous elevation)
- Moderate to high
- 24 hours (oral bioavailability)
- Orally active but produces sustained GH elevation rather than pulsatile release; disrupts natural secretory rhythms over time
- GHRP-6 acetate for growth hormone release occupies the middle ground: strong GH response without the cortisol elevation of Hexarelin or the selectivity trade-offs of Ipamorelin. The appetite effect—often cited as a drawback—becomes useful in research exploring ghrelin's role in metabolic regulation or cachexia models. Hexarelin desensitizes GHS-R1a receptors within 2–3 weeks of daily dosing, requiring washout periods; GHRP-6 shows minimal desensitization across 8–12 week protocols when dosed 2–3 times daily.
- For researchers combining secretagogues with GHRH analogs, GHRP-6 pairs effectively with CJC1295 Ipamorelin 5MG 5MG stacks or standalone Sermorelin. The synergistic GH release amplification applies across all GHRP analogs, but GHRP-6's lower cost per milligram and stable acetate formulation make it the workhorse peptide in budget-conscious labs.